list glp 1 receptor agonist of approved and pending GLP-1 medications Benefits and Risks of GLP-1
Description
N Engl J Med 387, 205216 (2022)
All findings to date derive from preclinical and early investigational data
Wilmington, DE
Amycretin is a next-generation unimolecular dual GLP-1/amylin receptor agonist that showed up to 24.3% weight loss in early trials, substantially exceeding semaglutide and potentially exceeding even CagriSema
If your goal is to lose 10 to 15 pounds for a specific purpose on a defined timeline, phentermine efficacy may be sufficient, and its 12-week treatment window may actually align with your needs
Liu D, Zhang Y, Liu Y, Hou L, Li S, Tian H, et al
